Thermo Fisher Scientific

Wednesday, April 13, 2022 at 2pm EST | 1pm CST | 11am PST Selecting raw materials for developing and manufacturing is not a trivial decision. Join us and learn how to avoid mistakes in raw material selection that can delay or prevent a promising mRNA therapeutic or vaccine from reaching the market..

One of the harsher realities to balance in the biotechnology and life sciences industries is that success in the lab is not the same as success in business, and you have to run a successful business to keep the lab going. Kurt Gielen, co-founder and chief business officer of Medace, knew he didn’t belong in the lab but also that a career in the biotech business was his calling. Now he’s leveraging his 20 years of experience in the industry to help young companies strike that balance between business and science. Medace offers an innovative co-working environment where research and entrepreneurship meet – and grow. Kurt shares his path from the lab, across the globe, and eventually to this unique Belgium-based incubator committed to turning research into reality and discusses why he’s committed to making Medace’s resources and knowledge accessible to fledgling biotech companies all over the world.

A simple UHPLC-CAD platform was developed for confident and accurate characterization of identity, purity and ratio of lipid components in lipid nanoparticle (LNP) formulations.

When university and industry researchers work in tandem to conquer big challenges in medicine, they can achieve much more together than they ever could apart. Sue Fletcher, a pioneer in RNA therapeutic and Chief Scientific Officer at PYC Therapeutics, know this firsthand. She has spent decades in the field and is the co-developer of some revolutionary genetic therapies for treating rare diseases. Here, Dr. Fletcher speaks with BioPharm International about her work in this field, her incredible career, and how she’s inspiring young scientists in this complex area.

Cell and gene therapies may well be some of the most important recent advancements in modern medicine. The way they work, however, is very complex and completely different from any pill that simply addresses symptoms. So who are the pioneers in this field and what dares them to ask “what if”? In this episode of the Building Biotechs podcast series sponsored by Thermo Fisher Scientific, learn from Ainslie Little, senior vice president of corporate strategy at BlueRock Therapeutics, how her company’s cell & gene platform is breaking new ground in this important space.

One of the greatest unexplored spaces of the world is the microbiome, a bustling network of trillions of microorganisms living inside each of us. If we could learn more about them, the advancements we’d make in healthcare and other fields would be incredible. This line of thinking is what spurred Tom Jarvie and Mark Driscoll to found Shoreline Biome, maker of the most complete end-to-end microbiome sample prep kits on the market. Hear their incredible story in this Building Biotechs podcast.

In just a few years, MAKO Medical has become a thriving healthcare disruptor by nimbly navigating the lab diagnostics waters with creativity and heart—helping patients and bringing joy to the communities it serves. In this episode of the Building Biotech podcast series from BioPharm International (sponsored by Thermo Fisher Scientific), hear the inspiring story of how founders Josh Arant and Chad Price turned their dream into a reality.

In this paper, we present an alternative targeted metabolite profiling approach using high resolution accurate mass (HRAM) mass spectrometry with full scan analysis.

Wastewater monitoring has been widely adopted by scientists to effectively detect and monitor infectious pathogens. Methods of detection and surveillance for SARS-CoV-2 are outlined in this paper and can be adapted for other pathogens.

Wednesday, June 23, 2021 at 10am EDT| 7am PDT| 3pm BST| 4pm CEST

Use an HRAM LC-MS approach to cell culture media metabolite profiling to develop a targeted quantitative assay that monitors and quantifies multiple classes of cell culture media metabolites simultaneously in a single LC-MS run. Demonstrate that the developed quantitative assay can be used to support upstream processing optimization and quality control with excellent quantitative performance, high throughput and robustness.

A new approach using the novel, easy-to-connect Thermo Scientific MAbPac RP capillary column for determining glycosylation site occupancy of therapeutic antibodies from the analysis of their tryptic digest.

***Session 1: Thursday, April 22, 2021, 10am EDT, Session 2: Thursday, April 22, 2021, 11am EDT, Session 3: Thursday, April 22, 2021, 1pm EDT*** A drug’s journey from development to manufacturing to patients is paved with roadblocks and potholes; many threats can derail bio/pharmaceutical processes. Potential solutions to such pitfalls have been discussed for years; however, few manufacturers have embraced technology and process advances to proactively ensure drug supply chain continuity.

***Available Now!*** In this webinar, Mike Knierman, Eli Lilly, will discuss the use of mass spectrometry to identify unique sequences from SARS-CoV-2 spike glycoprotein extracellular domain in a complex with human leukocyte antigen class II molecules on antigen presenting cells from healthy donors. This work exemplifies the value-add of mass spectrometry in vaccine development. *On Demand until March 30, 2022*

Learn about the use of the MAbPac RP capillary column for utmost sensitivity and excellent selectivity for the mass spectrometric analyses of intact proteins and mAb subunits.

Three major workflows for characterizing biopharmaceuticals on a LC-MS platform: intact mass analysis under native and denaturing conditions, subunit analysis complemented with Middle-Down analysis, and peptide mapping.

***Live: Tuesday, Feb. 23, 2021 at 11am EST | 8am PST | 4pm GMT | 5pm CET*** In this webinar, Mike Knierman, Eli Lilly, will discuss the use of mass spectrometry to identify unique sequences from SARS-CoV-2 spike glycoprotein extracellular domain in a complex with human leukocyte antigen class II molecules on antigen presenting cells from healthy donors. This work exemplifies the value-add of mass spectrometry in vaccine development. *On Demand until Feb. 23, 2022*

This study demonstrates the use of the workflow for sequence variant assessment and to monitor the variability of product quality attributes in biosimilar when compared to its originator.